<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916535</url>
  </required_header>
  <id_info>
    <org_study_id>367/2021/Oss/AOUFe</org_study_id>
    <nct_id>NCT04916535</nct_id>
  </id_info>
  <brief_title>Prospective Multicenter Study on Mitral Annular Disjunction</brief_title>
  <acronym>MAD-NesS</acronym>
  <official_title>Observational Cohort Prospective Multicenter Study on Mitral Annular Disjunction (MAD) - MAD multiceNter Study (MAD-NesS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Ferrara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Ferrara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational cohort prospective multicenter study on patients with mitral annular&#xD;
      disjunction (MAD). MAD is defined as a separation (≥1 mm) between the atrial wall-mitral&#xD;
      valvular junction and the left ventricular free wall during end-systole&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mitral annular disjunction (MAD) is a structural abnormality of the mitral annulus, defined&#xD;
      as a separation (≥1 mm) between the atrial wall-mitral valvular junction and the left&#xD;
      ventricular free wall during end-systole. This abnormality is significantly associated with&#xD;
      the presence of mitral valve prolapse (MVP), but it can also be observed in normal hearts.&#xD;
      MAD-related hypermobility of the mitral apparatus and the consequent posterior systolic&#xD;
      curling determine a mechanical stress of the infero-basal wall and papillary muscle. This&#xD;
      phenomenon leads to myocardial hypertrophy and fibrosis, creating an arrhythmogenic substrate&#xD;
      and a source of electrical instability. For this reason, the analysis of left ventricle by&#xD;
      cardiac magnetic resonance plays a pivotal role in the identification of predictors of fatal&#xD;
      arrhythmic events, such as sudden cardiac death (SCD). Taking into account that MAD could be&#xD;
      present without MVP, some studies analyzed the association between MAD and arrhythmic events.&#xD;
      They showed that MAD itself is a risk marker of electrical instability supporting the&#xD;
      existence of an emerging clinical entity: the MAD arrhythmic syndrome. An in deep analysis of&#xD;
      MAD patients and their characteristics in terms of EKG, types of arrhythmia,&#xD;
      echocardiographic parameters and cardiac magnetic resonance (CMR) data and long-term events&#xD;
      is lacking.&#xD;
&#xD;
      The present study is ideated and conducted to fill this gap and collect information regarding&#xD;
      management and outcome of patients with MAD&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2028</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Observational cohort prospective multicenter study on patients with MAD</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological findings associated with MAD</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage of subjects with MAD whom deeper analysis with cardiological visit, electrocardiogram (ECG), 24-hour ECG Holter monitoring and cardiac magnetic resonance (CMR) identifies pathological findings. Pathological findings are defined as follows: -T wave inversion in inferolateral leads at ECG&#xD;
frequent premature ventricular complexes (&gt;1000/24h)&#xD;
non-sustained ventricular arrythmias&#xD;
sustained ventricular arrythmias&#xD;
severe mitral regurgitation&#xD;
myocardial fibrosis with a non-ischemic pattern, especially of papillary muscles and inferolateral wall. The primary endpoint will be considered achieved if at least one of the above mentioned paramentrs will be found in the patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>surgery for mitral valve</measure>
    <time_frame>5 years</time_frame>
    <description>occurrence of mitral surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sudden cardiac death</measure>
    <time_frame>5 years</time_frame>
    <description>occurrence of sudden cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aborted cardiac arrest</measure>
    <time_frame>5 years</time_frame>
    <description>occurrence of aborted cardiac arrest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ventricular arrhythmia</measure>
    <time_frame>5 years</time_frame>
    <description>occurrence of non-sustained and/or sustained ventricular tachycardia</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Mitral Valve Disease</condition>
  <arm_group>
    <arm_group_label>diagnostic flow</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all patients with MAD as assessed during routine transthoracic echocardiography will undergo to the following further exams: i) 12-lead electrocardiogram (ECG), ii) 24-hour ECG monitoring, iii) cardiac magnetic resonance imaging (CMR), iv) cardiological visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic flow</intervention_name>
    <description>exams to estimate the risk of adverse events in patients with MAD</description>
    <arm_group_label>diagnostic flow</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Subject aged ≥18 years and &lt;65 years&#xD;
&#xD;
          -  Evidence of MAD during routine echocardiography clinically indicated by treating&#xD;
             physician for any reason&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        • Patient's refusal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabetta Tonet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Ferrara</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chiara Manzalini, BsC</last_name>
    <phone>0532239898</phone>
    <phone_ext>+39</phone_ext>
    <email>chiara88manzalini@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Veronica Lodolini, BsC</last_name>
    <phone>0532236450</phone>
    <phone_ext>+39</phone_ext>
    <email>ldlvnc@unife.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Ferrara</name>
      <address>
        <city>Ferrara</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabetta Tonet, MD</last_name>
      <phone>0532239898</phone>
      <phone_ext>+39</phone_ext>
      <email>tonet.elisabetta@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Rita Pavasini, MD</last_name>
      <phone>053236450</phone>
      <phone_ext>+39</phone_ext>
      <email>pvsrti@unife.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Ferrara</investigator_affiliation>
    <investigator_full_name>Gianluca Campo</investigator_full_name>
    <investigator_title>Full Professor Cardiologist</investigator_title>
  </responsible_party>
  <keyword>mitral annular disjunction</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

